Mainstream neuroscience frames dopamine as a biological reward signal, obscuring its role in sustaining capitalist exploitation of attention, labor, and consumption. Recent research reveals dopamine’s modulation by social hierarchy and environmental stressors, challenging the myth of individual ‘deficiency’ in mental health. The narrative ignores how pharmaceutical and tech industries profit from pathologising normal emotional responses to systemic oppression.
The narrative is produced by elite neuroscience journals (Nature) and funded by pharmaceutical/tech conglomerates, serving their interests in medicalising emotional distress to sell drugs and surveillance tech. It obscures the role of neoliberal capitalism in creating the conditions for dopamine dysregulation, framing the problem as individual rather than structural. The framing legitimises profit-driven interventions while ignoring collective solutions rooted in community care.
Eight knowledge lenses applied to this story by the Cogniosynthetic Corrective Engine.
Indigenous traditions frame dopamine dysregulation as a symptom of disconnection from land, community, or ancestral wisdom. The Māori concept of *whanaungatanga* (relational health) posits that dopamine imbalances stem from broken social bonds, not biochemical deficits. Ayurveda’s *ojas* (vital essence) theory suggests dopamine is a byproduct of balanced *prana* (life force), disrupted by processed foods and sedentary lifestyles.
Dopamine was first isolated in 1957, coinciding with the rise of consumer capitalism and the medicalisation of mental health. The 1980s ‘chemical imbalance’ theory emerged alongside Big Pharma’s push for SSRI antidepressants, mirroring the earlier racial pseudoscience of IQ testing. The current dopamine narrative reflects the neoliberal turn toward biopolitical control of populations via neurotechnologies.
In Tibetan medicine, dopamine dysregulation is treated with *srog-zin* (life-force stabilisers) like saffron and controlled breathing, emphasising environmental harmony. Japanese *shinrin-yoku* (forest bathing) reduces cortisol and regulates dopamine through biophilic design, contrasting with Western lab-based studies. Amazonian plant medicines like *ayahuasca* modulate dopamine via 5-HT2A receptors, offering non-pathologising alternatives to SSRIs.
Recent studies show dopamine’s role in salience detection, not just reward, with stress and hierarchy modulating its release. Environmental toxins (e.g., microplastics, pesticides) disrupt dopamine pathways, yet are rarely studied in mainstream neuroscience. Epigenetic research reveals dopamine gene expression is shaped by early-life trauma, challenging the ‘biological destiny’ narrative.
Artists like Yayoi Kusama use repetitive patterns to induce dopamine-mediated trance states, subverting pharmaceutical control. Sufi whirling dervishes achieve sustained dopamine release through rhythmic motion and breathwork, aligning with modern flow-state research. Psychedelic art movements (e.g., Alex Grey) visualise dopamine’s role in mystical experiences, offering non-clinical pathways to altered states.
Neurocapitalism may soon deploy AI-driven dopamine hacking via personalised ads, VR environments, and brain-computer interfaces. Scenario modelling suggests a 2035 tipping point where 30% of global GDP is spent on ‘neuro-optimisation’ interventions, exacerbating inequality. Regenerative futures require designing environments that naturally regulate dopamine through biophilic architecture and communal labour.
Black and Indigenous communities are overdiagnosed with dopamine-related disorders (e.g., ADHD, schizophrenia) due to racial bias in diagnostic criteria. Women’s dopamine responses are pathologised as ‘hormonal’ rather than contextual (e.g., postpartum stress). Migrant workers face chronic dopamine dysregulation from exploitative labour conditions, yet their embodied knowledge is excluded from neuroscience.
The original framing omits the historical commodification of dopamine (e.g., ADHD medication markets, social media algorithms), indigenous perspectives on emotional regulation (e.g., Ayurveda’s sattvic mind-states), and the role of colonial extractivism in creating environments that dysregulate dopamine. It also ignores the racialised and classed dimensions of dopamine research, where Black and working-class bodies are disproportionately pathologised.
An ACST audit of what the original framing omits. Eligible for cross-reference under the ACST vocabulary.
Redirect 50% of neuroscience funding to Indigenous researchers studying dopamine through traditional frameworks (e.g., Māori *whakapapa*-based neurobiology). Establish collaborative studies with Amazonian healers to map plant-based dopamine modulators, integrating Western and traditional methods. Prioritise research on collective care models (e.g., Ubuntu-based therapy) over individualised pharmaceutical solutions.
Enforce strict limits on social media algorithms that exploit dopamine loops, following the EU’s Digital Services Act model. Tax corporations (e.g., Meta, TikTok) that profit from attention extraction to fund community mental health programs. Mandate algorithmic transparency for neurotechnologies (e.g., brain-computer interfaces) to prevent corporate surveillance of emotional states.
Incorporate forest bathing zones, community gardens, and noise-reduction policies in urban planning to naturally regulate dopamine. Pilot ‘dopamine parks’ with diverse flora to study their impact on stress biomarkers. Partner with Indigenous land stewards to restore ecosystems that historically supported balanced dopamine function (e.g., pre-colonial Amazonian agroforestry).
Replace ADHD/SSRIs with peer-led support circles using somatic practices (e.g., dance, drumming) proven to regulate dopamine. Train ‘dopamine doulas’ in marginalised communities to provide culturally safe alternatives to clinical care. Advocate for universal basic services (e.g., housing, childcare) that reduce chronic stress, the primary driver of dopamine dysregulation.
The dopamine narrative is a microcosm of neoliberal biopolitics, where a complex neurochemical system is reduced to a marketable ‘deficiency’ to be ‘fixed’ by pharmaceuticals and surveillance tech. This framing obscures how colonial capitalism, from the transatlantic slave trade to Silicon Valley’s attention economy, has systematically disrupted dopamine’s role in sustaining life—not just reward. Indigenous epistemologies reveal dopamine as a relational force, not an individualised pathology, while historical analysis shows its weaponisation in racialised medicalisation (e.g., the ‘crack epidemic’ moral panic). The solution lies in dismantling neurocapitalism’s extractive logics, replacing them with regenerative systems—biophilic cities, decolonised science, and communal care—that restore dopamine’s original function: harmonising humans with each other and the living world. Actors like the WHO, Indigenous-led research collectives, and municipal governments must collaborate to implement these pathways before the dopamine economy fully colonises human consciousness.